{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,12]],"date-time":"2026-02-12T14:38:15Z","timestamp":1770907095496,"version":"3.50.1"},"reference-count":37,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2007,7,31]],"date-time":"2007-07-31T00:00:00Z","timestamp":1185840000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["J of Applied Toxicology"],"published-print":{"date-parts":[[2008,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Diorganotin(IV) compounds, R<jats:sub>2<\/jats:sub>SnCl<jats:sub>2<\/jats:sub> are often tetrahedral, and structurally resemble the active platinum compounds, i.e. cisplatin, and consequently a large number of such complexes have been tested for antitumor activity. A structural correlation with biological activity for diorganotin(IV) complexes has shown that active species are associated with complexes having Sn\u2013N bonds longer than 2.39 \u00c5 which in turn determines the formation of a tin\u2013DNA complex. In view of these, a series of diorganotin(IV) dichloride complexes of N\u2010(2\u2010pyridylmethylene)arylamine (nitrogen\u2010chelating ligands) has been synthesized and characterized on the basis of IR, NMR and <jats:sup>119<\/jats:sup>Sn\u2010M\u00f6ssbauer studies. In the present study, an attempt was made to determine the comparative antiproliferative and antitumor effect of diorganotin(IV) complexes with different alkyl groups [Me<jats:sub>2<\/jats:sub>SnCl<jats:sub>2<\/jats:sub>\u00b7L<jats:sup>1<\/jats:sup> (OTC\u20101), Et<jats:sub>2<\/jats:sub>SnCl<jats:sub>2<\/jats:sub>\u00b7L<jats:sup>2<\/jats:sup> (OTC\u20102) and <jats:sup>n<\/jats:sup>Bu<jats:sub>2<\/jats:sub>SnCl<jats:sub>2<\/jats:sub>\u00b7L<jats:sup>2<\/jats:sup> (OTC\u20103)]. The present study in human lymphocytes demonstrated that these diorganotin(IV) complexes could block the cell cycle progression and induce sister chromatid exchanges (SCEs) significantly, however, with respect to the induction of chromosome aberrations (CAs) it was very mild. Both the levels of p53 and p16 proteins were raised after diorganotin(IV) treatment and such induction was maximum in the OTC\u20103 treated samples. The antitumor activity was determined in accordance with the US National Cancer Institute (NCI) standard protocol for primary screening in Dalton's lymphoma that was maintained by serial intraperitoneal transplantation. The T\/C (treated\/control) value was increased (186% with OTC\u20103) when diorganotin(IV) was given after transplantation. The data suggest that the OTC\u20103 has better antiproliferative and antitumor activity and endogenous glutathione level has no influence on the effect of OTC\u20103. Copyright \u00a9 2007 John Wiley &amp; Sons, Ltd.<\/jats:p>","DOI":"10.1002\/jat.1290","type":"journal-article","created":{"date-parts":[[2007,7,31]],"date-time":"2007-07-31T11:47:27Z","timestamp":1185882447000},"page":"430-438","source":"Crossref","is-referenced-by-count":37,"title":["Cell proliferation inhibition and antitumor activity of novel alkyl series of diorganotin(IV) compounds"],"prefix":"10.1002","volume":"28","author":[{"given":"Biplob","family":"Koch","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tushar S. Basu","family":"Baul","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anupam","family":"Chatterjee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2007,7,31]]},"reference":[{"key":"e_1_2_1_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/0192-0561(93)90038-Z"},{"key":"e_1_2_1_3_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1099-0739(199807)12:7<503::AID-AOC746>3.0.CO;2-P"},{"key":"e_1_2_1_4_1","first-page":"207","article-title":"Crystal structure of dichlorodimethyl[N\u2010(2\u2010Pyridyl methylene)\u20103\u2010toluidine]tin, C15H18Cl2N2Sn","volume":"214","author":"Basu Baul S","year":"1999","journal-title":"Z. Kristallogr. (NCS)"},{"key":"e_1_2_1_5_1","first-page":"209","article-title":"Crystal structure of dichlorodimethyl[N\u2010(2\u2010pyridyl methylene)\u20104\u2010toluidine]tin, C15H18Cl2N2Sn","volume":"214","author":"Basu Baul S","year":"1999","journal-title":"Z. Kristallogr"},{"key":"e_1_2_1_6_1","first-page":"211","article-title":"Crystal structure of dichlorodimethyl[N\u2010(2\u2010pyridyl methylene)\u20103\u2010toluidine]tin, C15H18Cl2N2Sn","volume":"214","author":"Basu Baul S","year":"1999","journal-title":"Z. Kristallogr. (NCS)"},{"key":"e_1_2_1_7_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm00061a007"},{"key":"e_1_2_1_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0022-328X(00)92672-X"},{"key":"e_1_2_1_9_1","doi-asserted-by":"publisher","DOI":"10.1007\/s002040050488"},{"key":"e_1_2_1_10_1","first-page":"255","article-title":"The chemotherapeutic properties of Tin compounds.","volume":"12","author":"Crowe AJ","year":"1987","journal-title":"Drugs Future"},{"key":"e_1_2_1_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0020-1693(00)88160-8"},{"key":"e_1_2_1_12_1","doi-asserted-by":"publisher","DOI":"10.1016\/0304-3835(84)90078-8"},{"key":"e_1_2_1_13_1","doi-asserted-by":"publisher","DOI":"10.1191\/096032799678839437"},{"key":"e_1_2_1_14_1","doi-asserted-by":"publisher","DOI":"10.1006\/taap.1997.8265"},{"key":"e_1_2_1_15_1","doi-asserted-by":"publisher","DOI":"10.1002\/0470864052.ch22"},{"key":"e_1_2_1_16_1","first-page":"59","article-title":"In vitro antiproliferation effects, toxicity profiles in vivo in mice and antitumor activity in tumor bearing mice of five diorganotin compounds","volume":"9","author":"Gielen M","year":"1995","journal-title":"In Vivo"},{"key":"e_1_2_1_17_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00329173"},{"key":"e_1_2_1_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/0092-8674(93)90499-G"},{"key":"e_1_2_1_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/0165-1218(80)90144-5"},{"key":"e_1_2_1_20_1","volume-title":"Caffeine and Chromosomes","author":"Khilman BA","year":"1977"},{"key":"e_1_2_1_21_1","doi-asserted-by":"publisher","DOI":"10.1385\/CBB:33:2:175"},{"key":"e_1_2_1_22_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.89.16.7491"},{"key":"e_1_2_1_23_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-100-5-704"},{"key":"e_1_2_1_24_1","doi-asserted-by":"publisher","DOI":"10.1007\/BF00286427"},{"key":"e_1_2_1_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/(SICI)1098-2280(1997)29:1<98::AID-EM13>3.0.CO;2-C"},{"key":"e_1_2_1_26_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0010-8545(01)00399-X"},{"key":"e_1_2_1_27_1","doi-asserted-by":"publisher","DOI":"10.1177\/096032719401301210"},{"key":"e_1_2_1_28_1","volume-title":"The Hydrophobic Fragmental Constant","author":"Rekker RF","year":"1977"},{"key":"e_1_2_1_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1053-4296(96)80024-5"},{"key":"e_1_2_1_30_1","doi-asserted-by":"publisher","DOI":"10.1191\/096032799678839437"},{"key":"e_1_2_1_31_1","doi-asserted-by":"publisher","DOI":"10.1002\/ijc.11344"},{"key":"e_1_2_1_32_1","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2222.1998.00312.x"},{"key":"e_1_2_1_33_1","doi-asserted-by":"publisher","DOI":"10.1006\/taap.1999.8633"},{"key":"e_1_2_1_34_1","doi-asserted-by":"publisher","DOI":"10.1615\/JEnvironPatholToxicolOncol.v20.i4.100"},{"key":"e_1_2_1_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1383-5718(01)00289-3"},{"key":"e_1_2_1_36_1","unstructured":"1995 The Woodlands TX USA TEXAN Single crystal structure analysis software. Version 1.7.1. Molecular structure corporation"},{"key":"e_1_2_1_37_1","doi-asserted-by":"crossref","first-page":"1201","DOI":"10.1016\/S0022-3565(25)12398-7","article-title":"Induction of apoptosis by organotin compounds in vitro: Neuronal protection with antisense oligonucleotides directed against stannin","volume":"276","author":"Thompson TA","year":"1996","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"e_1_2_1_38_1","doi-asserted-by":"publisher","DOI":"10.1093\/nar\/gkg468"}],"container-title":["Journal of Applied Toxicology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fjat.1290","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/jat.1290","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,15]],"date-time":"2025-10-15T15:26:49Z","timestamp":1760542009000},"score":1,"resource":{"primary":{"URL":"https:\/\/analyticalsciencejournals.onlinelibrary.wiley.com\/doi\/10.1002\/jat.1290"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2007,7,31]]},"references-count":37,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2008,5]]}},"alternative-id":["10.1002\/jat.1290"],"URL":"https:\/\/doi.org\/10.1002\/jat.1290","archive":["Portico"],"relation":{},"ISSN":["0260-437X","1099-1263"],"issn-type":[{"value":"0260-437X","type":"print"},{"value":"1099-1263","type":"electronic"}],"subject":[],"published":{"date-parts":[[2007,7,31]]}}}